Aclaris Therapeutics, Inc. (ACRS)

In January 2026, Aclaris announced positive interim results from its Phase 1a trial of ATI-052 and initiated Phase 1b trials. In December 2025, Aclaris Therapeutics was added to the NASDAQ Biotechnology Index (NBI). In November 2025, the company reported its Q3 2025 financial results and presented positive results from the Phase 2a trial of ATI-2138. In December 2024, the stock saw a major spike following a licensing deal for ATI-045 and a subsequent $80 million secondary offering. In February 2025, Aclaris' stock had dropped nearly 70% since September 2023.

Aclaris Therapeutics, Inc. primarily generates revenue from licensing agreements and contract research, rather than from the commercial sale of approved products. Therefore, direct demand seasonality for its products and services is not a significant factor at this stage. The company's financial performance and stock price are more heavily influenced by clinical trial results, regulatory milestones, and strategic partnerships.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, operating through Therapeutics and Contract Research segments. The Therapeutics segment develops therapies for immuno-inflammatory diseases, while the Contract Research segment provides laboratory services. Its pipeline includes Zunsemetinib (ATI-450), ATI-2138, Bosakitug (ATI-045), ATI-052, and ATI-1777 (Lepzacitinib).

Aclaris Therapeutics, Inc. is headquartered in Wayne, Pennsylvania, and primarily operates in the United States. Its licensing agreements, such as the one for ATI-1777 with Pediatrix Therapeutics, extend its commercialization rights to Greater China.

Aclaris Therapeutics has faced challenges with its brand reputation due to past clinical program failures, leading to a significant stock drop. However, recent positive results from trials of ATI-1777 and ATI-052, along with the company's inclusion in the NASDAQ Biotechnology Index, suggest a potential shift in reputation. Despite these positive developments, skepticism remains due to past failures.

Aclaris Therapeutics, Inc. has high institutional ownership, with 98.34% of its stock held by institutions. As of January 9, 2026, the company had 201 institutional owners and shareholders holding a total of 90,372,453 shares. Individual insider ownership accounts for only 5.60% of the stock.